Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors

Anita K. Nivedha, Christofer S. Tautermann, Supriyo Bhattacharya, Sangbae Lee, Paola Casarosa, Ines Kollak, Tobias Kiechle and Nagarajan Vaidehi
Molecular Pharmacology April 2018, 93 (4) 288-296; DOI: https://doi.org/10.1124/mol.117.110395
Anita K. Nivedha
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christofer S. Tautermann
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supriyo Bhattacharya
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sangbae Lee
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Casarosa
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ines Kollak
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Kiechle
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagarajan Vaidehi
Department of Molecular Immunology, Beckman Research Institute of the City of Hope, Duarte, California (A.K.N., S.B., S.L., N.V.); Departments of Medicinal Chemistry (C.S.T.) and Immunology and Respiratory Diseases Research (I.K., T.K.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; and Corporate Department of Business Development and Licensing, C.H. Boehringer Sohn, Ingelheim, Germany (P.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

G-protein-coupled receptors (GPCRs) mediate multiple signaling pathways in the cell, depending on the agonist that activates the receptor and multiple cellular factors. Agonists that show higher potency to specific signaling pathways over others are known as “biased agonists” and have been shown to have better therapeutic index. Although biased agonists are desirable, their design poses several challenges to date. The number of assays to identify biased agonists seems expensive and tedious. Therefore, computational methods that can reliably calculate the possible bias of various ligands ahead of experiments and provide guidance, will be both cost and time effective. In this work, using the mechanism of allosteric communication from the extracellular region to the intracellular transducer protein coupling region in GPCRs, we have developed a computational method to calculate ligand bias ahead of experiments. We have validated the method for several β-arrestin–biased agonists in β2-adrenergic receptor (β2AR), serotonin receptors 5-HT1B and 5-HT2B and for G-protein–biased agonists in the κ-opioid receptor. Using this computational method, we also performed a blind prediction followed by experimental testing and showed that the agonist carmoterol is β-arrestin–biased in β2AR. Additionally, we have identified amino acid residues in the biased agonist binding site in both β2AR and κ-opioid receptors that are involved in potentiating the ligand bias. We call these residues functional hotspots, and they can be used to derive pharmacophores to design biased agonists in GPCRs.

Footnotes

    • Received August 24, 2017.
    • Accepted January 16, 2018.
  • This work was funded by Boehringer-Ingelheim and by National Institutes of Health National Institute of General Medical Sciences [Grant R01-GM097296].

  • https://doi.org/10.1124/mol.117.110395.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

  • Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 93 (4)
Molecular Pharmacology
Vol. 93, Issue 4
1 Apr 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identifying Functional Hotspot Residues for Biased Ligand Design in G-Protein-Coupled Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Identifying Functional Hotspots for Biased Ligand Design

Anita K. Nivedha, Christofer S. Tautermann, Supriyo Bhattacharya, Sangbae Lee, Paola Casarosa, Ines Kollak, Tobias Kiechle and Nagarajan Vaidehi
Molecular Pharmacology April 1, 2018, 93 (4) 288-296; DOI: https://doi.org/10.1124/mol.117.110395

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Identifying Functional Hotspots for Biased Ligand Design

Anita K. Nivedha, Christofer S. Tautermann, Supriyo Bhattacharya, Sangbae Lee, Paola Casarosa, Ines Kollak, Tobias Kiechle and Nagarajan Vaidehi
Molecular Pharmacology April 1, 2018, 93 (4) 288-296; DOI: https://doi.org/10.1124/mol.117.110395
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics